Lantheus Holdings, Inc. (LNTH)

Nasdaq: LNTH · In Vitro & In Vivo Diagnostic Substances · North Billerica, MA · filing with the SEC since 2014

Full chart Alerts Compare

Grade6.8

◀ Past 8.7● Present 7.1▶ Future 4.5

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The companyfiscal 2025, as filed

Revenue$1.54B+0.5%

Net income$234M-25.2%

Earnings per share$3.41-21.8%

Operating cash flow$390M-28.4%

Cash$359M-60.7%

Debt$569M+0.6%

Shareholders’ equity$1.09B+0.2%

Shares, diluted68.4M-4.5%

Return on equity21.4%

The recordfrom its filings

Filings in 202677

Newest filingNov 12 · SCHEDULE 13D/A

Annual reportFeb 26, 2026

Quarterly reportNov 5, 2026

Next report due10-K by Mar 1

Insider sales, 12 months$0.00

Insider buys, 12 months$0.00

Patents granted195

Filer categoryLarge accelerated filer

Trailing twelve months to Sep 2026Revenue $1.56BNet income $270MCash from operations $409Mthe four newest filed quarters added

Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.

Revenue and net income by fiscal yearRevenueNet income

16171819202122232425

As filed, in USD. Nothing here is a forecast.

News

Nov 12, 2026 · SEC EDGAR · Form SCHEDULE 13D/A

Activist holder update, amended

Open the filing on sec.gov

Nov 10, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

Nov 5, 2026 · SEC EDGAR · Form 10-Q

Quarterly report

Open the filing on sec.gov

Nov 5, 2026 · SEC EDGAR · Form 8-K

Results released

Open the filing on sec.gov

Nov 5, 2026 · SEC EDGAR · Form SCHEDULE 13G/A

Large holder update, amended

Open the filing on sec.gov

Oct 30, 2026 · SEC EDGAR · Form SCHEDULE 13G/A

Large holder update, amended

Open the filing on sec.gov

Oct 22, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

Oct 14, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

Oct 2, 2026 · SEC EDGAR · Form DEFA14A

Extra proxy material

Open the filing on sec.gov

Oct 2, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.

SI brieffrom the record

Core business

Lantheus Holdings, Inc. is classed by the SEC under In Vitro & In Vivo Diagnostic Substances (industry code 2835), based in North Billerica, MA. PYLARIFY was 64% of fiscal 2025 revenue.

Newest on the record

Activist holder update, amended on Nov 12. Before it, current report on Nov 10.

What is due next

The 10-K for the period to Dec 31, 2026, due by Mar 1, 2027.

About LNTH

Lantheus Holdings, Inc. is classed by the SEC under In Vitro & In Vivo Diagnostic Substances (industry code 2835), based in North Billerica, MA. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $1.5 billion and a profit of $234 million (its filed statements).

IndustryIn Vitro & In Vivo Diagnostic Substances

HeadquartersNorth Billerica, MA

Business modelProduct business

ExchangeNasdaq

Filing since2014

Fiscal year endsDec 31

SEC number (CIK)1521036

Peers on fileNEOG, IDXX, QDEL, NTLA

Who runs it

Financial performance

In fiscal 2025 Lantheus Holdings’s revenue was $1.54 billion, up 0.5% from $1.53 billion the year before. Net income was $233.6 million, down 25.2%.

Annual report, filed Feb 26, 2026.

Financial statements

The grade

Lantheus Holdings grades 6.8 of 10 against its own industry, the 18 companies in In Vitro & In Vivo Diagnostic Substances. All nine metrics are read as filed.

◀ Past8.7

● Present7.1

▶ Future4.5

How the grade is made

Forecast

Every forecast is registered before the outcome, with the rule that settles it. A miss stays on the page.

Company forecasts

SI Assistanton LNTH · research, not advice